Physician profile
Corey H Evans
NPI 1790891182
$3,707.01
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,840 · 2020: $1,490 · 2021: $377.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $603.95 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $441.91 | 2019-2021 | |
| Pfizer INC. | $398.92 | 2019-2021 | |
| Novo Nordisk INC | $275.22 | 2019-2021 | |
| Amarin Pharma, INC. | $227.29 | 2019-2021 | |
| Smith+Nephew, INC. | $198.49 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $155.48 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.18 | 2019-2021 | |
| Silk Road Medical, INC. | $137.57 | 2019 | |
| Lilly USA, LLC | $135.29 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $131.62 | 2019-2021 | |
| Abbvie INC. | $114.98 | 2019 | |
| Amgen INC. | $113.58 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $80.80 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $68.41 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $51.60 | 2019 | |
| Organogenesis INC. | $50.52 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $48.80 | 2019 | |
| Merck Sharp & Dohme LLC | $41.31 | 2019 | |
| Astellas Pharma US INC | $35.90 | 2019-2020 | |
| Allergan, INC. | $26.66 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $24.06 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $22.96 | 2019 | |
| Abbott Laboratories | $22.48 | 2020 | |
| Acell, INC. | $20.24 | 2019 | |
| Integra Lifesciences Corporation | $19.65 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $18.14 | 2021 | |
| Optinose US, INC. | $17.57 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.84 | 2019 | |
| Zyla Life Sciences, INC. | $15.04 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.91 | 2019 | |
| Glaxosmithkline, LLC. | $14.04 | 2019 | |
| Ethicon US, LLC | $13.60 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corey Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.